Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Toward Immune Biomarkers for Tolerance and GvHD in Humans (BioGvHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02319226
Recruitment Status : Unknown
Verified February 2019 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was:  Active, not recruiting
First Posted : December 18, 2014
Last Update Posted : February 19, 2019
Sponsor:
Collaborator:
National Research Agency, France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

Graft-versus-Host Disease (GVHD), is the most frequent and severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). Much of our knowledge on the pathophysiology of GVHD has been gained from experimental models but far less from the study of the disease in humans. Recent developments in basic biology open new avenues to the development of biomarker sets that could predict GVHD severity and prognosis that could be tested and validated through well-designed multicenter clinical trials.

The main goal of this project is to further our understanding of the pathogenic mechanisms of human GVHD on one hand, and of functional immune tolerance on the other. Furthermore, this study aims at setting up a clinically relevant biomarker set in human GVHD and immune tolerance in a discovery cohort.

The objectives of this project are:

1. To define phenotypic, functional and molecular correlates of acute GVHD early after HSCT/at its onset 2. To study thymic reconstitution and the T-cell repertoire after HSCT during period 2 3. To identify functional and molecular correlates of immune tolerance in long-term survivors of HSCT 4. Preparing for biomarker validation into a clinical trial We propose a prospective analysis of a cohort of 680 patients transplanted from an HLA-identical sibling donor at Saint Louis hospital. Analyses will be performed during 3 critical, clinically relevant, periods.

  1. Period 1: Analysis at the onset of GVHD, or at the time of engraftment 30 days after HSCT in patients not developing GVHD. An additional blood sample will also be analyzed 90 days after HSCT.
  2. Period 2: Thymic function analysis using measurements of T-cell receptor excision circles (TREC) will be performed at 6 and 12 months post-transplant for all patients. T-cell receptor analysis on sorted T-cell populations will be performed by NGS.
  3. Period 3: In "tolerant" patients (patients more than 2 years after HSCT not requiring immunosuppressive treatment), or in patients still requiring immunosuppressive therapy after 2 years. We will also analyze the corresponding immune parameters for each donor.

The longitudinal design of this study will allow us to provide an integrated view of GVHD pathophysiology and mechanisms of immune tolerance in human.

Prospectively identified phenotypic, molecular or functional biomarkers will then be tested, in a subsequent study, from biological materials prospectively collected within the French wide CryoStem cohort. Thus, as the final task of this project, we will perform statistical analyses taking into account confounding clinical variables influencing the outcome (i.e. GVHD-related death or tolerance). Preparing for a clinical trial will need moving from classical Bioinformatics analyses into clinically relevant statistical analyses that include sequential biological measurement in the discovery set cohort. Main points that will be taken into accounts for this task are the followings;

  1. Transplant-related mortality (TRM) can be estimated in the range of 20%; 2year post-allogeneic HSCT
  2. TRM is mostly (even if totally) due to GVHD and its associated immune deficiency
  3. GVHD cumulative incidence can be estimated in the range of 40%
  4. 80 patients will be prospectively studied and 30 patients will be analyzed (cross sectional study) for part 3 only.
  5. Since GVHD-related mortality and tolerance are mutually exclusive situation the optimal calculation for the validation cohort can be expected
  6. This calculation will be the basis for the proposal of an interventional clinical trial.

Condition or disease Intervention/treatment
Bone Marrow Transplantation Graft vs Host Disease Hematopoietic Stem Cell Transplantation Other: Transplantation from an HLA-identical sibling donor

Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Toward Immune Biomarkers for Tolerance and GvHD in Humans
Study Start Date : May 2014
Actual Primary Completion Date : February 2019
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine



Intervention Details:
  • Other: Transplantation from an HLA-identical sibling donor
    The study will include a cohort of 60 patients transplanted from an HLA-identical sibling donor.


Primary Outcome Measures :
  1. acute Graft-versus-Host Disease (GVHD) early after allogeneic hematopoietic stem cell transplantation (HSCT) [ Time Frame: 30 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients transplanted from an HLA-identical sibling donor
Criteria

Inclusion Criteria:

  • Patients transplanted from an HLA-identical sibling donor

Exclusion Criteria:

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02319226


Locations
Layout table for location information
France
Hopital siant-Louis
Paris, France, 75019
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
National Research Agency, France
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02319226    
Other Study ID Numbers: PRTSN1339002N
First Posted: December 18, 2014    Key Record Dates
Last Update Posted: February 19, 2019
Last Verified: February 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases